{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:42:11Z","timestamp":1791160931157,"version":"4.1.0"},"reference-count":53,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,4,2]],"date-time":"2014-04-02T00:00:00Z","timestamp":1396396800000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Neurology"],"published-print":{"date-parts":[[2014,4]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>There is considerable interest in using bumetanide, a chloride importer Na\u2010K\u2010Cl cotransporter antagonist, for treatment of neurological diseases, such as epilepsy or ischemic and traumatic brain injury, that may involve deranged cellular chloride homeostasis. However, bumetanide is heavily bound to plasma proteins (\u223c98%) and highly ionized at physiological pH, so that it only poorly penetrates into the brain, and chronic treatment with bumetanide is compromised by its potent diuretic effect.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>To overcome these problems, we designed lipophilic and uncharged prodrugs of bumetanide that should penetrate the blood\u2013brain barrier more easily than the parent drug and are converted into bumetanide in the brain. The feasibility of this strategy was evaluated in mice and rats.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Analysis of bumetanide levels in plasma and brain showed that administration of 2 ester prodrugs of bumetanide, the pivaloyloxymethyl (BUM1) and<jats:italic>N,N<\/jats:italic>\u2010dimethylaminoethylester (BUM5), resulted in significantly higher brain levels of bumetanide than administration of the parent drug. BUM5, but not BUM1, was less diuretic than bumetanide, so that BUM5 was further evaluated in chronic models of epilepsy in mice and rats. In the pilocarpine model in mice, BUM5, but not bumetanide, counteracted the alteration in seizure threshold during the latent period. In the kindling model in rats, BUM5 was more efficacious than bumetanide in potentiating the anticonvulsant effect of phenobarbital.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interpretation<\/jats:title><jats:p>Our data demonstrate that the goal of designing bumetanide prodrugs that specifically target the brain is feasible and that such drugs may resolve the problems associated with using bumetanide for treatment of neurological disorders. ANN NEUROL 2014;75:550\u2013562<\/jats:p><\/jats:sec>","DOI":"10.1002\/ana.24124","type":"journal-article","created":{"date-parts":[[2014,2,25]],"date-time":"2014-02-25T10:00:44Z","timestamp":1393322444000},"page":"550-562","source":"Crossref","is-referenced-by-count":107,"title":["A novel prodrug\u2010based strategy to increase effects of bumetanide in epilepsy"],"prefix":"10.1002","volume":"75","author":[{"given":"Kathrin","family":"T\u00f6llner","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Toxicology, and Pharmacy University of Veterinary Medicine Hannover Germany"},{"name":"Center for Systems Neuroscience Hannover Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Brandt","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology, and Pharmacy University of Veterinary Medicine Hannover Germany"},{"name":"Center for Systems Neuroscience Hannover Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"T\u00f6pfer","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology, and Pharmacy University of Veterinary Medicine Hannover Germany"},{"name":"Center for Systems Neuroscience Hannover Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerda","family":"Brunhofer","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry University of Vienna Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Erker","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry University of Vienna Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Gabriel","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry University of Vienna Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W.","family":"Feit","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology, and Pharmacy University of Veterinary Medicine Hannover Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Lindfors","sequence":"additional","affiliation":[{"name":"Department of Biosciences and Neuroscience Center University of Helsinki Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Kaila","sequence":"additional","affiliation":[{"name":"Department of Biosciences and Neuroscience Center University of Helsinki Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"L\u00f6scher","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology, and Pharmacy University of Veterinary Medicine Hannover Germany"},{"name":"Center for Systems Neuroscience Hannover Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,4,2]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncpneuro0883"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2012.05.045"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1076510"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0602979103"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2761-07.2007"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.00986.x"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03203.x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1301"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00287a014"},{"key":"e_1_2_8_11_1","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0022-3565(25)30556-2","article-title":"A comparative diuretic and tissue distribution study of bumetanide and furosemide in the dog","volume":"197","author":"Cohen MR","year":"1976","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0633-10.2010"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(79)90108-4"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(80)90141-0"},{"key":"e_1_2_8_15_1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0022-3565(25)21841-9","article-title":"High anticonvulsant potency of gamma\u2010aminobutyric acid (GABA)mimetic drugs in gerbils with genetically determined epilepsy","volume":"226","author":"L\u00f6scher W","year":"1983","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(85)90034-2"},{"key":"e_1_2_8_17_1","unstructured":"T\u00f6llnerK BrandtC BrunhoferG et al.Strategies to enhance the brain concentration of bumetanide. Paper presented at: Society for Neuroscience Annual Meeting; November 13\u201317 2010; San Diego CA."},{"key":"e_1_2_8_18_1","unstructured":"T\u00f6pferM T\u00f6llnerK BrandtC et al.Effects of the NKCC1\u2010inhibitor bumetanide on alterations in seizure susceptibility and GABAergic transmission after status epilepticus in mice. Paper presented at: American Epilepsy Society 65th Annual Meeting; December 2\u20136 2011; Baltimore MD."},{"issue":"6","key":"e_1_2_8_19_1","first-page":"52","article-title":"Development and characterization of new prodrugs of bumetanide in combination with the monooxygenase inhibitor piperonyl butoxide for anti\u2010epileptogenesis","volume":"52","author":"T\u00f6llner K","year":"2011","journal-title":"Epilepsia"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.1989.sp017762"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2006.107086"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1977.tb03209.x"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/88.4.555"},{"key":"e_1_2_8_24_1","first-page":"447","article-title":"Serum esterases in mice, rats and man using the two\u2010dimensional zymogram method","volume":"6","author":"Hunter RL","year":"1961","journal-title":"Ann Histochim"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2010.11.005"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2012.08143.x"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1993.tb13648.x"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2011.02.018"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057148"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2012.124"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-008-9009-8"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.1987.253.2.C177"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.2000.80.1.211"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-001-0521-y"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-2236(03)00068-7"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.059139"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2005.09.054"},{"key":"e_1_2_8_38_1","unstructured":"HochmanD Haglund M.Evidence that bumetanide suppresses epileptiform activity in adult primate cortex independent of effects on GABA\u2010A signalling. Paper presented at: American Epilepsy Society 63th Annual Meeting; December 4\u20138 2009; Boston MA."},{"key":"e_1_2_8_39_1","unstructured":"HochmanDW PartridgeJJ.Methods and compositions for the treatment of neuropsychiatric disorders with bumetanide and furosemide analogs. PatentUS20060089350A1.2006."},{"key":"e_1_2_8_40_1","unstructured":"HochmanDW PartridgeJJ.Methods and compositions using NKCC cotransporter inhibitors for the treatment of neuropsychiatric and addictive disorders. PatentWO2007047698A2.2007."},{"key":"e_1_2_8_41_1","unstructured":"WanaskiS PartridgeJJ CollinsS.Preparation of bumetanide furosemide piretanide azosemide and torsemide analogs and therapeutic compositions containing same for treating disorders involving the Na+K+Cl\u2010 cotransporter and GABAA receptors. PatentWO2010085352A2.2010."},{"key":"e_1_2_8_42_1","unstructured":"WanaskiS CollinsS KincaidJ.Arylsulfonamide derivatives as sodium\u2010#potassium\u2010chloride cotransporter inhibitors and their preparation compositions and methods of use. PatentWO2012018635A2.2012."},{"key":"e_1_2_8_43_1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0090-9556(25)06000-3","article-title":"Identification of the urinary metabolites of 14C\u2010bumetanide in the rat and their excretion by rats and dogs","volume":"4","author":"Kolis SJ","year":"1976","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2008.04.047"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-0102(02)00093-7"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(03)03528-5"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02048.x"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21229"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awr041"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/pr.2012.7"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn1430"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-4886(86)90160-3"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-0082(97)00035-X"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03378.x"}],"container-title":["Annals of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fana.24124","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ana.24124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T22:47:26Z","timestamp":1746139646000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ana.24124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["10.1002\/ana.24124"],"URL":"https:\/\/doi.org\/10.1002\/ana.24124","archive":["Portico"],"relation":{},"ISSN":["0364-5134","1531-8249"],"issn-type":[{"value":"0364-5134","type":"print"},{"value":"1531-8249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}